ALLO
Allogene Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.69
−2.31%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.73
From 52W high−44.77%
Volume12.72M
Market cap$583.88M
P/E (TTM)—
P/S (TTM)125.8x
Div yield—
Key dataSep 18, 2026
Open
$1.73
From 52W high
−44.77%
Volume
12.72M
Market cap
$583.88M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.1x
P/E (TTM)
—
RSI (14)
34.9
MomentumView details →
1D Return
−2.31%
YTD Return
+22.26%
SummaryUpdated Jun 1, 2026
Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a clinical-stage immuno-oncology biotechnology company founded in 2017 and headquartered in South San Francisco, California. The company went public in October 2018 and has positioned itself as a pioneer in developing "off-the-shelf" allogeneic CAR T cell therapies for cancer treatment and autoimmune diseases. Unlike traditional CAR T therapies that require extracting and modifying a patient's own immune cells, Allogene's approach uses genetically engineered T cells from healthy donors that can be manufactured in advance and stored for immediate use when needed.
Similar companies
Latest newsMore news →
Allogene Therapeutics announced that Chief Financial Officer Geoffrey Parker will retire effective November 6, 2026.18d agoDimensional Fund Advisors LP increased its stake in Allogene Therapeutics, Inc. by 25.5% during the first quarter, acquiring an additional 243,839 shares, according to a 13F filing.39d ago